Welcome to our dedicated page for Omeros news (Ticker: OMER), a resource for investors and traders seeking the latest updates and insights on Omeros stock.
The Omeros Corporation (NASDAQ: OMER) news page on Stock Titan aggregates company announcements, clinical updates, regulatory milestones, and financial disclosures in one place. Omeros is a biopharmaceutical company focused on first-in-class small-molecule and protein therapeutics for complement-mediated diseases, cancers, and addictive or compulsive disorders, and its news flow reflects this broad development agenda.
A major theme in recent Omeros news is YARTEMLEA (narsoplimab-wuug), the company’s fully human monoclonal antibody that inhibits MASP-2 in the lectin pathway of complement. The U.S. FDA has approved YARTEMLEA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adults and children two years of age and older. News items detail the approval decision, clinical data on complete response and survival, safety information, and plans for the U.S. market launch, as well as conference calls discussing this milestone.
Investors and clinicians following OMER news will also find updates on regulatory reviews in Europe, peer-reviewed publications on TA-TMA outcomes with narsoplimab, and developments in Omeros’ broader pipeline. These include progress with OMS1029, the long-acting MASP-2 inhibitor; OMS527 for cocaine use disorder, supported by a grant from the National Institute on Drug Abuse; and oncology and Targeted Complement Activating Therapy (T-CAT) programs.
Another recurring news topic is Omeros’ strategic transactions and financing. Releases describe the asset purchase and license agreement with Novo Nordisk for the MASP-3 inhibitor zaltenibart (OMS906), including upfront and milestone payment structures and retained rights, as well as registered direct offerings, at-the-market equity sales, and quarterly financial results. Bookmark this page to review OMER headlines, official press releases, and related commentary as they are issued.
Omeros (Nasdaq: OMER) will host a live webcast of its Annual Meeting of Shareholders on June 6, 2024, at 10:00 a.m. Pacific Time. Shareholders of record as of April 18, 2024, can attend, vote, and submit questions online using a 16-digit control number. The meeting will include a general corporate overview and Q&A session. Guests can attend but won't have voting or questioning privileges. The event will be recorded and available later on the company's website.
Omeros (NASDAQ: OMER) has completed a series of strategic financial transactions aimed at strengthening its balance sheet and extending the maturity of its debt. The company repurchased $118.1 million, or 55%, of its outstanding convertible notes due in 2026 at 75% of their notional value, resulting in $51 million in total debt extinguishment. The repurchase was funded through a new $67 million secured four-year term loan maturing in June 2028 and $21 million in cash. The new credit facility includes a $25 million delayed draw term loan for potential narsoplimab commercialization, with no equity component, preventing shareholder dilution.
The transactions strengthen Omeros' financial position, enabling flexibility to manage the remaining 2026 notes and support potential narsoplimab commercialization. Omeros retains all future potential value of capped calls associated with the original 2026 notes. The loans carry a competitive interest rate of adjusted term SOFR plus 8.75%, maturing on June 3, 2028. The company maintains a cash balance of $230.3 million, sufficient to fund operations and debt service into 2026.
Omeros (Nasdaq: OMER) reported a net loss of $37.2 million or $0.63 per share for Q1 2024, up from $33.7 million or $0.54 per share in Q1 2023. The net loss from continuing operations was $43.9 million, compared to $39.7 million in the prior year. Key developments include receiving $115.5 million from amending the OMIDRIA royalty purchase agreement with DRI Healthcare Acquisitions LP. Omeros had $230.3 million in cash and short-term investments by the end of March 2024, up by $58.5 million from year-end 2023.
Clinical progress includes the resubmission plan for narsoplimab BLA and the ongoing Phase 2 and 3 trials for OMS906 in PNH and C3G. OMS1029 is set for a Phase 2 trial later in 2024. OMS527 continues its development for cocaine use disorder funded by a $6.69 million NIDA grant. Omeros earned $9.4 million in OMIDRIA royalties from U.S. sales of $31.2 million in Q1 2024.
Operating expenses for Q1 2024 rose to $39.0 million from $35.7 million in Q1 2023, mainly due to higher R&D costs. Interest expense increased to $8.2 million from $7.9 million. The company’s management will host a conference call to discuss the results and business updates.
Omeros (NASDAQ: OMER) will announce its financial results for the quarter and year ended March 31, 2024, on May 15, 2024. The company's management will host a conference call and webcast to discuss the financial results and recent developments.
Omeros (OMER) announced that interim analysis data from its ongoing Phase 2 study of OMS906 in patients with paroxysmal nocturnal hemoglobinuria has been selected for podium presentation at the 2024 European Hematology Association (EHA) Hybrid Congress. OMS906 is an investigational inhibitor of MASP-3 targeting the alternative pathway of complement. The EHA Congress will take place in Madrid, Spain from June 13-16, 2024, where two additional poster presentations related to OMS906 will also be featured.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.